Recombinant adeno-associated virus comprising VEGFR Truncated Soluble cDNA and gene therapeutic agent comprising the same

A VEGFR-1, VEGFR-2 technology, applied in the field of recombinant adeno-associated virus containing Truncated Soluble cDNA of VEGFR and gene therapy agents containing the above components, can solve the problems such as no major breakthroughs

Inactive Publication Date: 2007-01-31
SCT
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, although research on polynucleotides is also continuing, no major breakthroughs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant adeno-associated virus comprising VEGFR Truncated Soluble cDNA and gene therapeutic agent comprising the same
  • Recombinant adeno-associated virus comprising VEGFR Truncated Soluble cDNA and gene therapeutic agent comprising the same
  • Recombinant adeno-associated virus comprising VEGFR Truncated Soluble cDNA and gene therapeutic agent comprising the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1: Cloning of pAAV plasmids containing genes that inhibit neovascularization

[0046] In order to use pAAV-FIX cis plasmad DNA (US 6,093,292) to insert VEGF-A (NCBI accession #NM_003376 for human) cDNA into pAAV-FIX cis plasmad DNA in the antisense direction according to the cloning method, use VEGF-A isoform antisense Trans-gene constructs of pAAV-AShVEGF-A were produced by replacing the factor IX cDNA gene contained in pAAV-FIX cis plasmad DNA with the sense cDNA. In addition, trans-gene constructs of pAAV-AShVEGF-A-IRES-EGFP in which VEGF-Aisoform antisense cDNA was linked to IRES-EGFP were prepared.

[0047] The truncated soluble cDNAs of VEGFR-1 (Flt-1; NCBIaccession#NM_002019 for human) and VEGFR-2 (Kdr / Flk-1; NCBIaccession#AF06365 8 for human), which act as receptors that interact with the three isoforms of VEGF, were also used The same method was used for insertion or replacement to produce trans-gene constructs of pAAV-TShVEGFR-1 and pAAV-TShVEGFR-2. ...

Embodiment 2

[0085] Embodiment 2: Making the rAAV vector of gene therapy agent for inhibiting neovascularization

[0086] In order to make a recombinant AAV (rAAV) vector for gene therapy, in addition to each pAAV plasmid DNA made in Example 1, the AAV rep-cap plasmid DNA (pAAV-RC plasmid) expressing the AAV rep part and cap part is also needed. , Stratagene Co., USA) and adenovirus helper plasmid (pHelper plasmid, Stratagene Co., USA). After all the above three plasmid DNAs were transfected into HEK293 (human embryonic kidney 293; ATCCCRL-1573) cells and cultured for 96 hours, the HEK293 cells were collected and ultrasonically disrupted, and the recombinant AAV (rAAV) particles were subjected to CsCl density gradient centrifugation for three times. , and then collect the fraction with RI (Refractive Index) of 1.37-1.41 g / ml for purification and separation.

[0087] The titration method of the above-mentioned isolated rAAV particles is as follows: PCR primer [CMV F1 (SEQ ID NO: 14): 5′-GG...

Embodiment 3

[0113] Embodiment 3: The treatment of cancer cell line culture and rAAV vector gene therapy agent

[0114] In order to study the anticancer effect of preventing cancer metastasis in vitro, human colorectal cancer cell line (T84: ATCC CCL-248) and human lung cancer cell line (LCSC#1: WO 02 / 061069) and human gastric cancer cell lines (NUGC3, MKN45, MKN74) and other five cancer cell lines. In order to test the anti-cancer therapeutic effect of recombinant rAAV on the above-mentioned cancer cell lines, each branch of the above-mentioned cancer cell lines on 6well plate 10 5 After cells / well cultured for 24 hours, add a total M.O.I. of 10 5 Various combinations of neovascularization-inhibiting rAAV vectors were cultured for 24 hr. In this example, the negative control (negative control) selects the same cell population that has not been treated with rAAV and the rAAV vector (rAAV-EGFP) that does not insert VEGF antisense and only expresses GFP, and is the same as the recombinant ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a gene therapeutic agent using truncated soluble cDNA of VEGF receptor protein (VEGFR) and adeno-associated virus(AVV) system, and more particularly, relates to a gene therapeutic agent specific to large intestine cancer, bladder cancer and/or lung cancer, comprising a rAAV vector containing truncated soluble cDNA of VEGFR, and a rAAV vector containing the said vector and VEGF-A anti-sense cDNA. The gene therapeutic agent according to the present invention reduces the growth of tumors by inhibiting the expression and function of VEGF involved in angiogenesis necessary for the proliferation and metastasis of tumors. Thus, the inventive gene therapeutic agent can be effectively used to treat cancer at a gene level.

Description

technical field [0001] The present invention relates to a gene therapy agent utilizing truncated solublecDNA of VEGF receptor protein (VEGFR) and utilizing adeno-associated virus (AAV) system, especially a kind of rAAV vector comprising truncated solublec DNA comprising VEGFR and containing said vector and VEGF -A colorectal cancer, bladder cancer and / or lung cancer specific gene therapy agent of rAAV vector of antisense (antisense) cDNA. Background technique [0002] No matter at home or abroad, cancer mortality is increasing year by year. Worldwide, cancer, infectious diseases and cardiovascular diseases are the leading causes of human death. According to the World Health Report of the World Health Organization (WHO), in 2004, 7,121,00 people, accounting for 12.5% ​​of all deaths, died from cancer. And because of eating habits, environmental changes and life extension, it is estimated that in the next 25 years, the number of cancer-causing people will increase at a rate ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/861C12N15/12C12N7/01A61K48/00A61P35/00
CPCC07K14/71C12N2750/14143A61P35/00C12N15/11
Inventor 朴基娘
Owner SCT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap